Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
36.00
-0.01 (-0.01%)
Apr 25, 2025, 4:00 PM EDT - Market closed
PRAX Revenue
In the year 2024, Praxis Precision Medicines had annual revenue of $8.55M with 249.53% growth. Praxis Precision Medicines had revenue of $7.46M in the quarter ending December 31, 2024, with 1,349.13% growth.
Revenue (ttm)
$8.55M
Revenue Growth
+249.53%
P/S Ratio
75.37
Revenue / Employee
$73,733
Employees
116
Market Cap
725.88M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
PRAX News
- 18 days ago - Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies - GlobeNewsWire
- 22 days ago - Praxis Precision Medicines to Participate in Upcoming April Conferences - GlobeNewsWire
- 22 days ago - Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade) - Seeking Alpha
- 2 months ago - Praxis Precision Medicines Provides Update on Essential3 and Corporate Update - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Present at Two February Investor Conferences - GlobeNewsWire
- 3 months ago - Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities - GlobeNewsWire
- 4 months ago - Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome - GlobeNewsWire